Immuno Oncology Session

Dr.Bassim Al Bahrani is working as a Director at National Oncology Center, Royal Hospital Oman since 2010. He is an honorary Fellow of the Royal College of physicians and surgeons of Glasgow, and Ph.D. from University of Rome Tor Vergata.

Dr. Bhawna Sirohi started her oncology career at Tata Memorial centre (TMC), Mumbai in 1994 and completed training at Royal Marsden NHS Foundation Trust, UK. She serves in Max Super specialty Hospital and is currently an honorary consultant with QMUL, London. At TMC in 2012-2014, she set up GI medical oncology &medical oncology information system (MOIS) for e-prescribing chemotherapy. She has been involved in initial setting up of cancer centres in Sangrur and Mohali, Punjab for TMC. She has piloted use of virtual consults using PROM & PREM in London.

Dr. Deborah Mukherji is an Associate Professor of Clinical Medicine (Oncology) and joined the faculty of the AUBMC in June 2012. Dr Mukherji completed her advanced specialty training in Medical Oncology at Guys and St Thomas’s NHS Foundation Trust, London UK and was awarded a Post-Graduate Diploma in Oncology from the Institute of Cancer Research, University of London in 2011.

Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.

Dr Fathi Azribi is a Consultant Medical Oncologist and Chief of Medical Oncology Division at Tawam Hospital. He graduated from Tripoli University, Libya, then completed specialty training in Oncology in the UK and obtained a Certificate of Completion of Training in Medical Oncology in October 2009. His main interest is in thoracic, breast, gynaecological and gastrointestinal malignancies; with expertise in treatment with chemotherapy, immunotherapy, hormonal and targeted therapy. He published several papers and abstracts in peer reviewed journals. He is also the Program Director of the medical oncology fellowship program at Tawam Hospital.

Giuseppe Curigliano, MD PhD, is Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. He is a clinician and researcher specialising in early drug development for patients with solid tumours with a special commitment to breast cancer. He has been a member of the Italian National Health Council since 2018 and, in 2019, he served as Chair of the Scientific Committee of The Lega Nazionale Lotta ai Tumori. 

Dr.Javier Cortes is a head of breast cancer and gynecological cancers at Hospital Universitario Ramón y Cajal in Madrid, Spain, as well as Clinical Investigator in the breast cancer research program at Vall d’Hebron Institute of Oncology in Barcelona, Spain.He is one of the European leaders in the field of HER2+ breast cancer, and has led fundamental trials that resulted in the approval of pertuzumab, eribulin and everolimus for metastatic breast cancer. He continues to actively participate in national and international clinical investigations to develop molecularly targeted therapies, such as CDK 4/6 inhibitors, and immunotherapies.Dr. Cortés is on the Scientific Committee of ESMO and is an active member of ASCO and the Spanish Society of Medical Oncology.

Deputy director of the Perlmutter Cancer Center, and in that capacity works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex. Serve as codirector of the Melanoma Research Program, overseeing work in experimental therapeutics.

.

Dr. Diab has been working with NMC since May 2014 as Consultant Medical Oncologist. He completed his MD in 2004 from Karolinska University, Sweden. Subsequently, he completed his Certificate in Bone Marrow Transplantation in 2008 from Oncology Hospital, Radiumhemmet. Dr. Diab was instrumental in setting up the Oncology clinic at NMC hospital, where he implemented updated chemotherapy protocols according to the highest international and European standards. He has also set up a one of its kind, unique tumour board, which meets weekly to discuss all cancer cases to ensure that each patient’s treatment is personalised and most appropriate to his/her needs. This tumour board is multi-disciplinary & consists of the onco-surgeon, onco-pathologist & onco-radiologist in addition to allied specialities. Prior to joining NMC, he was a Consultant Medical Oncologist since 2008 in the West Gotland Region in Sweden that had 2 hospitals having capacities of 525 and 300 beds respectively. He was also instrumental in setting up and leading the oncology clinics of these hospitals while in Sweden. Dr. Diab manages his own Medical Oncology study and participates actively in many studies for different Tumour diagnosis. He is multilingual and can communicate fluently in English, Arabic, Swedish and has knowledge of conversational Norwegian and Danish.

Dr. Shaheenah Dawood’s specialty is Oncology and currently works as a Consultant Oncologist in Mediclinic City Hospital. She currently serves as president of the Excellence in Oncology Care (EIOC) congress that is held annually in Dubai and is Co-Chair of the Asia Pacific Breast Cancer Summit (APBCS) & APGCS.

“Solange Peters, MD, PhD, is a full professor and chair of medical oncology, as well as the thoracic malignancies program in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Prof. Peters has specialized in thoracic tumors, lung cancer, and pleural tumors. Prof. Peters is currently in charge of teaching and patient care in thoracic malignancies at Lausanne University, where she is building a translational program in collaboration with the Swiss Federal Institute of Technology and the Ludwig Institute. Her main fields of interest are new biomarkers discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. Her current research projects are mainly focused on innovative immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator and Foundation Council member of the European Thoracic Oncology Platform. Professor Peters has authored numerous peer-reviewed manuscripts and book chapters, acts as associate editor of the Annals of Oncology, serves on the editorial board of several other oncology journals, and was the deputy editor of the Journal of Thoracic Oncology for 10 years. Prof. Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) – where she created the Women for Oncology Committee and for which she is the youngest President ever for an extended time of 3 years 2020-2022, and the International Association for the Study of Lung Cancer (IASLC) – were she was a previous Board of Directors member. “

He is the founding Medical Director of Sarah Cannon Research Institute UK, and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the Hospital Corporation of America International Cancer Service Line. Dr. Arkenau has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma.